Navigation Links
NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials
Date:3/7/2013

University of Pennsylvania. 

DisclaimerStatements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medical Alarm Concepts Provides Investor Update - Signs Deal with Health Care Insurance Provider for Medical Alarms
2. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
3. Compass Diversified Holdings Provides Shareholders with 2012 Tax Information
4. Volcano Corporation Provides Additional Guidance For 2013
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
6. AcelRx Pharmaceuticals Provides Clinical Trial Updates
7. Masimo Reports Fourth Quarter and Full Year 2012 Financial Results; Provides 2013 Financial Guidance
8. US Peptides Provides New Article Discussing HGH and Athletic Performance
9. BioMed Realty Trust Provides Notice of Redemption of 7.375% Series A Cumulative Redeemable Preferred Stock
10. Genomic Health Announces Year-End 2012 Financial Results, Provides 2013 Financial Outlook
11. Breakthrough Procedure Provides Relief for Acid Reflux
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... MELBOURNE, Australia, Oct. 24, 2011 Key Points ... 2 trial for wet Age-related Macular Degeneration (AMD) ... Mesoblast,s allogeneic ("off-the-shelf") cells with anti-VEGF agent Wet AMD, ... forms in Asia and North America/Europe Anti-VEGF agents are ...
... today announced that it has received the Stroke Care ... placing it among the top 5 percent of hospitals ... mortality rates for stroke treatment and pulmonary services. ... with HealthGrades, Five-Star Rating and ranked as the number ...
Cached Medicine Technology:Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases 2Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases 3Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases 4Evergreen Named One of America's 100 Best Hospitals for Stroke Care 2Evergreen Named One of America's 100 Best Hospitals for Stroke Care 3
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
(Date:4/17/2014)... of Canadians surveyed said they would participate in public ... of genetic conditions, only 80 per cent said they ... sequence their newborns, genomes.,Most newborns in North America have ... two of life in which a tiny amount of ... about five to 54 conditions, depending on the state ...
(Date:4/17/2014)... as the leading weapon against the deadly disease could ... research indicating it simply needs to be administered differently. ... cheap anti-malarial drug chloroquine in treating and preventing the ... half a million people each year around the world. ... to chloroquine, but research carried out at the Australian ...
(Date:4/16/2014)... Ariz. April 15, 2014 The Translational Genomics ... at their annual Founders Dinner for their support of ... event took place March 28 in Scottsdale. , Catherine ... Ivy Foundation, received TGen,s John S. McCain Leadership Award, ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... of interoperable Health Information Technology (HIT) will be ... the U.S. healthcare system," Yul D. Ejnes, MD, FACP, ... Health today. "Unfortunately, without adequate financial incentives, small ... technological curve." Dr. Ejnes, a member of the Board ...
... launches first of three-part series, MONTCLAIR, N.J., July ... the launch of an educational Webcast series on,chronic pain ... chronic pain sufferer, Nikki Stone. The first in the,three-part ... You Back" is available today at http://www.painawareness.org ., ...
... July 24 Colombia has appointed Dallas sports,chiropractor, Dr. ... medical team,during the upcoming Olympic Games in Beijing. Dr. ... worked with the Costa,Rican team for the 2007 Pan ... a privilege to bring the profession to an international ...
... BURLINGTON, Mass., July 24 Palomar Medical,Technologies, Inc. (Nasdaq: ... devices for hair removal and other cosmetic treatments, will,hold ... financial,results on Thursday, July 31, 2008 at 11:30AM Eastern ... 362-4831 at 11:20 AM Eastern Time on,that day. The ...
... The University of Queensland is helping to increase medical ... advanced clinical training facility. , UQ,s Rural Clinical ... and Learning Centre to its portfolio, with space to ... adjacent to the Toowoomba Base Hospital in West Street, ...
... new research facility is planned to enable unprecedented understanding ... shape human behaviour. The 28.5 million funding comes ... Universities and Skills (DIUS), and will be used for ... be a collaboration between the Economic and Social Research ...
Cached Medicine News:Health News:ACP says Medicare should increase payments for physicians that use HIT to improve quality 2Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 2Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 3Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 4Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 5Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 6Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 7Health News:Colombia Appoints Dallas Chiropractor to Olympic Team 2Health News:Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008 2Health News:New $4.2m UQ medical center to boost rural doctor numbers 2Health News:£28.5M investment for groundbreaking new research facility 2
... Acid is a non-irritating rapid exfoliator. Lactic Acid ... to peel and exfoliating agents in skin care ... other exfoliators for a long period and want ... occurring human metabolite, and combined with the chemical ...
... is available in two innovative formulations: Level ... active). The Level I (40% active) formulation ... extract, which DCL scientists have identified and ... and calm the skin while the beneficial ...
... CosmoDerm and CosmoPlast are dermal fillers ... acne scars and other soft tissue contour ... of the lip border. The collagen in ... dermal tissue that is grown under controlled ...
... is a gel of ... species of bacteria, chemically ... suspended in phosphate,buffered saline ... and concentration of 20 ...
Medicine Products: